Biotech PR runs on a calendar you mostly don't control. Trial readouts, regulatory decisions, conference abstracts, and journal embargoes set the dates. Your job is to be ready for them and to say nothing that creates a problem for your clinical, regulatory, or legal teams.
This guide covers what makes life sciences communications different, who covers it, which milestones are genuinely news, and where companies get into trouble.
What makes biotech PR different
The news comes in discrete, scheduled events. Unlike software, where you could announce something any week, a biotech company has a finite set of moments: financing, IND clearance, trial initiation, data readouts, regulatory milestones, approvals, partnerships, and publications. Everything between those is relationship-building, not news.
Your readers include investors, and that changes the rules. For public companies, a press release is a disclosure document. Material information must be handled under securities rules, and selective disclosure is a serious matter. Even private companies with institutional investors should assume their releases are read as investor communications.
Scientific audiences check everything. Clinicians, principal investigators, and competitor scientists read your release. Overstating a result (a subgroup finding described as a primary endpoint, a surrogate marker described as clinical benefit) damages credibility with exactly the people you need.
Patients read it too. Families searching for a trial will find your announcement. That imposes an ethical obligation to be clear about what stage a program is at and what it does not yet show.
The outlets and beats that matter
Industry trades. These are the primary target for most announcements:
- Endpoints News, deeply read by the industry, covers clinical and business news
- STAT News covers clinical, policy, and business news, with strong investigative work
- Fierce Biotech and Fierce Pharma cover trial, deal, and company news
- BioPharma Dive, BioSpace, Pink Sheet and Scrip for regulatory and commercial
Business and general press. Reuters, Bloomberg, the Wall Street Journal, and the Financial Times cover financings, M&A, approvals, and controversies. Their healthcare reporters cover the sector, not individual programs, so the bar is approvals, big deals, or a story with public-health weight.
Scientific and clinical press. Nature Biotechnology, Science, NEJM Journal Watch, and specialty clinical publications reach the physicians who will eventually prescribe. Coverage here follows peer-reviewed publication, not your press release.
Conference-driven cycles. ASCO, AACR, ASH, JPMorgan Healthcare, and the specialty society meetings concentrate coverage into a few weeks a year. Abstract embargo rules are strict and non-negotiable, and violating one can pull your abstract. If embargo mechanics are new to you, learn the rules before you schedule anything.
Build your list around reporters who cover your therapeutic area and stage. An oncology reporter and a rare-disease reporter at the same outlet are different targets. Building a media list the right way matters more in biotech than almost anywhere else.
Milestones that are genuinely news
Roughly in order of coverage likelihood:
- Regulatory approvals and major decisions, including approval, complete response, breakthrough or fast track designation, and orphan designation.
- Pivotal or randomized trial results, positive or negative. Negative results get covered, so plan for that release before you have the data.
- Large financings and partnerships, particularly a pharma partner with disclosed economics. Use a funding release structure so the deal terms sit where investors and reporters look.
- Acquisitions and licensing deals.
- IND clearance and first patient dosed, which draws modest trade coverage but is a real signal to investors.
- Peer-reviewed publication of meaningful data.
- Senior scientific or clinical hires, and notable scientific advisory board additions.
- Manufacturing and capacity milestones, in cell and gene therapy especially.
What generally isn't news: conference attendance, poster presentations of early data, preclinical results in a single animal model, patent filings, advisory board expansions, and "we are pleased to announce our participation in." Run marginal items through the newsworthiness test rather than defaulting to a release.
Claims discipline and compliance traps
None of this is legal or regulatory advice. Every item below is a place where life sciences companies get into real trouble, and every one of them belongs in front of regulatory and securities counsel before publication.
Never state or imply efficacy or safety for an unapproved product. In the United States, promotional claims for investigational products are prohibited, and FDA has acted on company communications including press releases and social posts. Describe what the trial measured and what the data showed. Do not describe the product as effective, safe, or a treatment for anything until it is approved for that use.
Off-label promotion. For approved products, claims outside the label are a serious enforcement area. Marketing review exists for a reason, so do not route around it.
Endpoint honesty. State the primary endpoint, whether it was met, the statistical significance, the trial size, and the comparator. A statistically significant secondary endpoint in a trial that missed its primary is not a positive trial, and describing it as one is the fastest way to lose both reporters and investors.
Surrogate versus clinical endpoints. Biomarker movement is not survival. Say which one you measured.
Safety data. Serious adverse events belong in the release when material. Omitting them and having a reporter find them in a filing is far worse than disclosing them yourself.
Forward-looking statements. Public companies need proper safe-harbor language, and the phrasing of forward-looking claims is a securities matter. Private companies raising capital should be similarly careful. Material information must go out through compliant channels, so coordinate with counsel and, where relevant, your exchange's requirements.
Patient stories. Any patient identified in a release needs documented, informed consent, and privacy rules apply to anything drawn from clinical records.
Journal and conference embargoes. Breaking one can cost you the publication. Align your release timing with the embargo lift to the minute.
A realistic cadence
A clinical-stage company might issue six to twelve releases a year, and that is enough. The rhythm is event-driven, not calendar-driven.
- Around each catalyst: prepare the release, the Q&A, and a negative-result version well in advance. Have counsel review both versions before the data unblinds.
- Quarterly: one non-catalyst touchpoint: a publication, a scientific presentation, a leadership addition, or a data-driven perspective piece from your chief medical officer.
- Continuously: relationships with four or five reporters who cover your indication. The value of those relationships shows up on the day of a bad readout, when you need someone to report it accurately.
Two practical notes. First, prepare the negative-data release before you need it, because companies that draft it under pressure always overreach. Second, understand what distribution buys: a wire release creates the timestamped public record that investors, partners, and regulators expect to find, and for public companies that record is often required. It does not persuade a reporter to write a story. That job belongs to a direct, factual pitch to someone who covers your disease area, and how to write a media pitch email covers the mechanics.
Need a compliant distribution path for your next milestone? [See how it works](/how-it-works).